Pure Global AI
NCT06346691Not yet recruiting

Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease

Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease : A Randomized Crossover Study
Thammasat UniversityPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
COPD
Drug/Device/Intervention
Doxofylline
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Thammasat University
Timeline & enrollment
Phase
Phase 4
Start date
Apr 16, 2024
End date
Dec 31, 2024
Enrollment
20 participants
Primary outcome

Forced expiratory volume in 1 second (FEV1),Forced vital capacity (FVC),Forced expiratory flow at 25-75% of FVC (FEF25-75)

Summary

The goal of this clinical trial is to determine if doxofylline and procaterol are effective
 in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also
 assess the safety of both drugs.
 
 The main questions it aims to answer are:
 
 - Does doxofylline demonstrate a comparable bronchodilator effect to procaterol in COPD
 participants?
 
 - What medical problems do participants experience when taking doxofylline and
 procaterol?

ICD-10 classifications
Chronic obstructive pulmonary disease, unspecifiedOther chronic obstructive pulmonary diseaseOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedPulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06346691
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06346691 through Pure Global AI's free database. This Phase 4 trial is sponsored by Thammasat University and is currently Not yet recruiting. The study focuses on COPD. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.